Back to mobile site

Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel After Q4 Results

March 12, 2026 7:54 AM EDT Send to a Friend
Stifel analyst Laura Prendergast reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented, "On ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login